Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299045 | 0.83 | RORC (0.35) | ALDH1A1LMNAL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL299020 | 0.81 | L3MBTL1 (0.42) | ALDH1A1LMNAL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL25279271 | 0.81 | ACHE (0.33) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28056626 | 0.80 | ALDH1A1 (0.33) | ALDH1A1LMNAL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL16823687 | 0.76 | RORC (0.37) | — | |
| SCHEMBL24978140 | 0.76 | HTT (0.36) | ALDH1A1LMNAL3MBTL1HTTRECQL | |
| SCHEMBL25231234 | 0.75 | EPHX2 (0.37) | ALDH1A1LMNASMN1; SMN2RAB9AKMT2A | |
| SCHEMBL2003409 | 0.75 | KMT2A (0.48) | ALDH1A1SMN1; SMN2HTTPOLBGAA | |
| SCHEMBL16825515 | 0.74 | RORC (0.35) | ALDH1A1LMNARAB9ANPC1MAPT | |
| SCHEMBL16825256 | 0.73 | TRPV4 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-9663502-B2 | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160304505-A1 | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2016-10-20 | — | — | US | disclosed |
| WO-2015095788-A1 | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-9018228-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2427058-B1 | NEMATOCIDAL SULFONAMIDES | DU PONT (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140221203-A1 | NEMATOCIDAL SULFONAMIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735588-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140088309-A1 | NEMATOCIDAL SULFONAMIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-03-27 | — | — | US | disclosed |
| US-8623890-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120114624-A1 | NEMATOCIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2427058-A2 | NEMATOCIDAL SULFONAMIDES | E. I. du Pont de Nemours and Company (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129500-A2 | NEMATOCIDAL SULFONAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304505-A1 | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | ALDH1A1 360/4885LMNA 4222/4885L3MBTL1 3983/4885 |
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | PDK1, PDK2, PDK3 | ALDH1A1 1703/4885LMNA 715/4885L3MBTL1 1283/4885 |
| US-20140221203-A1 | NEMATOCIDAL SULFONAMIDES | NSFL1C, QSOX1, Q6ZSR9 | ALDH1A1 2283/4885LMNA 3730/4885L3MBTL1 760/4885 |
| US-20120114624-A1 | NEMATOCIDAL SULFONAMIDES | NSFL1C, QSOX1, Q6ZSR9 | ALDH1A1 2283/4885LMNA 3730/4885L3MBTL1 760/4885 |
| US-20140088309-A1 | NEMATOCIDAL SULFONAMIDES | NSFL1C, QSOX1, Q6ZSR9 | ALDH1A1 2283/4885LMNA 3730/4885L3MBTL1 760/4885 |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PDK2, PKM | ALDH1A1 1784/4885LMNA 853/4885L3MBTL1 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.